This trial is evaluating whether Default Genetics Referral Process will improve 1 primary outcome and 3 secondary outcomes in patients with Colorectal Carcinoma (CRC). Measurement will happen over the course of 3 months.
This trial requires 53 total participants across 1 different treatment group
This trial involves a single treatment. Default Genetics Referral Process is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Patients who have a life expectancy of less than 15 months should be offered adjuvant therapy with fluoropyrimidines and oxaliplatin. Patients will require intensive surveillance after completion of adjuvant therapy." - Anonymous Online Contributor
"With improved screening and detection techniques, there have been improvements in outcomes over the past 15 years. Improved treatment options have also contributed to an improvement in survival rates. The most recent studies are currently focused on better understanding of the molecular basis of colorectal cancer as well as improving our ability to diagnose and treat this disease." - Anonymous Online Contributor
"Seriousness depends largely on time. If diagnosed early enough, patients can survive up to five years with curative treatment. But if detected later, which is often the case, then survival drops significantly. Patients who present with advanced stages of disease have a poor prognosis. They may live only two months after diagnosis." - Anonymous Online Contributor
"Although many factors can influence the risk of CRC, lifestyle choices are one of the most important. The chance of developing CRC increases with obesity, alcohol consumption and lack of physical activity. Those who are physically inactive have a higher risk of developing CRC as compared to those who do exercise regularly\n" - Anonymous Online Contributor
"A default genetics referral process improves patients' QOL by better addressing issues related to physical symptoms and distress. This increases patient satisfaction and health care provider satisfaction while minimizing requests for additional tests." - Anonymous Online Contributor
"There are many different classes of drugs available for treating colorectal cancer. The most important factor that influences survival is stage at diagnosis. For patients with advanced disease only 5-FU and irinotecan are recommended as first line treatment. 5-FU remains the gold standard treatment for metastatic colorectal cancer and has shown excellent response rates with appreciable toxicity. Irinotecan is an effective second line treatment for chemotherapy resistant metastatic colorectal cancer but its adverse effects make it unsuitable for some patients. New chemotherapeutic agents such as oxaliplatin, docetaxel, capecitabine or fluorouracil are used in combination therapy to improve response rates." - Anonymous Online Contributor
"It is difficult to determine the actual number since most people diagnosed do not report their age, especially younger people. The average age at diagnosis appears to be around 60 years old with an increase in incidence of early presentations with a trend towards earlier presentation for younger people. This may be due to diagnostic delay because of lack of knowledge about colorectal cancer and poor survival rates of some early stage types of colorectal cancer." - Anonymous Online Contributor
"The use of ancillary treatments was highly variable across patients. The protocol was largely ad hoc. Most patients were referred to a default genetics service; however, only a minority underwent further testing for hereditary conditions." - Anonymous Online Contributor
"Results from a recent clinical trial confirms that colon cancer may be present as early as 6 years after diagnosis of any other type of malignancy. This suggests that screening for colorectal cancer should begin at least six years before diagnosis of any other malignancy." - Anonymous Online Contributor
"Survival rates are improving and have improved over the last decade in many countries and at all disease stages. This improvement has been associated with advances in staging and treatment strategies. The incidence of CRC remains high worldwide and has increased in recent decades. The prognosis depends on the stage of the tumour, its location, the presence of metastases, clinical status and the age of the patient at diagnosis. Survival rates vary widely by stage of the disease, though they seem to be greater than 56% in both early and late stages." - Anonymous Online Contributor
"Emerging trends in default genotype analysis will likely be applied to genetic counseling and gene therapy clinical research in the near future. It may be particularly helpful in cases involving rare disease and/or complex inheritance patterns. As an example, some studies involving children have indicated that a genetic diagnosis could help reduce risk of developing serious illness from a common genetic disease at a later time during childhood. In addition, using family history data can help identify families with greater risk of developing specific rare diseases. This information can then be used to guide interventions aimed at modifying risk factors." - Anonymous Online Contributor